The following article is the first of a three-part series in which we explore and clarify the challenges facing maintenance ...

Elis delivers very solid H1 2025 results Elis leverages its resilient and sustainable business model to continue delivering profitable growth, despite a challenging macro environment in Europe Confirm ...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed at ...